← FDA DRUG APPROVALS

FDA ANDA · ANDA213437

OSELTAMIVIR PHOSPHATE

Sponsor: UPSHER SMITH LABS

APPLICATION
ANDA213437
TYPE
ANDA
ORIGINAL APPROVAL
2026-01-22
LATEST ACTION
2026-01-22
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

OSELTAMIVIR PHOSPHATEDiscontinued
OSELTAMIVIR PHOSPHATE EQ 75MG BASE · CAPSULE · ORAL
OSELTAMIVIR PHOSPHATEDiscontinued
OSELTAMIVIR PHOSPHATE EQ 30MG BASE · CAPSULE · ORAL
OSELTAMIVIR PHOSPHATEDiscontinued
OSELTAMIVIR PHOSPHATE EQ 45MG BASE · CAPSULE · ORAL

Approval history

2026-01-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →